Ocera Therapeutics (OCRX) vs. Argos Therapeutics (ARGS) Financial Comparison

Ocera Therapeutics (NASDAQ: OCRX) and Argos Therapeutics (NASDAQ:ARGS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Ocera Therapeutics and Argos Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocera Therapeutics 0 3 1 0 2.25
Argos Therapeutics 0 3 0 0 2.00

Ocera Therapeutics currently has a consensus price target of $1.92, suggesting a potential upside of 9.52%. Argos Therapeutics has a consensus price target of $4.13, suggesting a potential upside of 2,331.37%. Given Argos Therapeutics’ higher possible upside, analysts plainly believe Argos Therapeutics is more favorable than Ocera Therapeutics.

Risk and Volatility

Ocera Therapeutics has a beta of 2.46, suggesting that its share price is 146% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Valuation & Earnings

This table compares Ocera Therapeutics and Argos Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ocera Therapeutics $610,000.00 76.05 -$26.89 million ($0.97) -1.80
Argos Therapeutics $950,000.00 15.73 -$53.02 million ($1.12) -0.15

Ocera Therapeutics has higher earnings, but lower revenue than Argos Therapeutics. Ocera Therapeutics is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

17.7% of Ocera Therapeutics shares are held by institutional investors. Comparatively, 18.4% of Argos Therapeutics shares are held by institutional investors. 7.2% of Ocera Therapeutics shares are held by company insiders. Comparatively, 28.2% of Argos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Ocera Therapeutics and Argos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ocera Therapeutics N/A -228.93% -103.71%
Argos Therapeutics -13,750.64% -1,532.49% -120.95%

Summary

Ocera Therapeutics beats Argos Therapeutics on 9 of the 13 factors compared between the two stocks.

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

What are top analysts saying about Ocera Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Ocera Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit